Testing IBI3016 injections in Japanese adults with mild to moderate high blood pressure
Tests single injections of IBI3016 in Japanese adults with mild to moderate hypertension.
Plain-language title generated from the registry record
Registry title: A Study of IBI3016 in Japanese Participants
Key facts
- Where
- Osaka, JapanSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07838220, who can take part
Where in Japan
- Medical Corporation Heishinkai OPHAC HospitalOsaka, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Innovent Biologics (Suzhou) Co. Ltd.
- Trial code
- NCT07838220
- Record updated
- 24 September 2026
- Original description
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.Read full original descriptionShow less
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
Inclusion: 1. Male or female participants aged 18-75 years (inclusive) at the time of informed consent; 2. Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin; 3. Office mean sitting SBP≥ 140 mmHg and < 170 mmHg at screening.
Exclusion: 4. With diseases that require treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors other than hypertension at screening; 5. Presence of serious active and uncontrolled physical conditions or medical history, which may be in a dangerous state during the use of the study drug, or interfere with the interpretation of efficacy and safety data of this study, as judged by the investigator prior to randomization; 1. Participants with secondary hypertension, including but not limited to the following conditions: obstructive sleep apnea; 2. History of orthostatic hypotension; 3. Current or history of intolerance to AECI, ARB, ARNI or direct renin inhibitor.